{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=9", "query": { "intervention": "Blood", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 20633, "total_pages": 2064, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T19:32:58.938Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02227199", "title": "Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-10-10", "completion_date": "2025-07-28", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227199" }, { "nct_id": "NCT02667587", "title": "An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Neoplasms" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Nivolumab Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 716, "start_date": "2016-05-09", "completion_date": "2024-04-09", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02667587" }, { "nct_id": "NCT05986916", "title": "Accurate Point of Care Liver Disease Diagnostics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NAFLD", "Nonalcoholic Fatty Liver" ], "interventions": [ { "name": "Liverscope® exam", "type": "DIAGNOSTIC_TEST" }, { "name": "MR exam", "type": "DIAGNOSTIC_TEST" }, { "name": "FibroScan® exam (optional)", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood draw", "type": "OTHER" }, { "name": "Body measurements", "type": "OTHER" }, { "name": "Questionnaires", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-08-03", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05986916" }, { "nct_id": "NCT00039130", "title": "Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 105, "start_date": "2002-05", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 31, "location_summary": "San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039130" }, { "nct_id": "NCT00735787", "title": "Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Adalimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2008-08", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2010-11-01", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Macon", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Windsor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00735787" }, { "nct_id": "NCT00379587", "title": "Rituximab for Prevention of Chronic GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "375 mg/m2 RRituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2006-09", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-03-19", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379587" }, { "nct_id": "NCT02864316", "title": "Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Induced by Prior Radiation Exposure" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2016-12", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864316" }, { "nct_id": "NCT07125534", "title": "Alcohol and the Social Brain: An Alcohol-Administration Hyperscanning Study Employing a Within-Subject Design", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alcohol Drinking", "Alcohol Use Disorder (AUD)", "Alcohol Intoxication", "Alcohol; Harmful Use", "Alcoholism", "Binge Drinking" ], "interventions": [ { "name": "Alcohol beverage", "type": "DRUG" }, { "name": "Control - non alcoholic beverage", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Illinois at Urbana-Champaign", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "21 Years to 30 Years" }, "enrollment_count": 200, "start_date": "2025-08-09", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 2, "location_summary": "Champaign, Illinois", "locations": [ { "city": "Champaign", "state": "Illinois" }, { "city": "Champaign", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07125534" }, { "nct_id": "NCT05393232", "title": "Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Dietitian-Assisted DASH groceries", "type": "BEHAVIORAL" }, { "name": "Self-directed shopping", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 176, "start_date": "2022-10-13", "completion_date": "2026-05-25", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05393232" }, { "nct_id": "NCT05397132", "title": "Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "Blood draw", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2022-05-27", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-19T19:32:58.938Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05397132" } ] }